The activating effects of EGF and VEGF-A on downstream genes including PLAU/R highlights the potential for anti-EGFR- and/or anti-VEGF- with anti-uPA/uPAR-targeting approaches for metastatic cSCC. The gene discussed is PLAU; the disease is skin squamous cell carcinoma.